A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and USlicensed Avastin®.
Status:
Active, not recruiting
Trial end date:
2021-08-20
Target enrollment:
Participant gender:
Summary
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare
the PK, safety and immunogenicity profile of MB02-DM with MB02-SP and US-Avastin® in healthy
male subjects.
During the course of the study, the similarity in pharmacokinetics will be assessed by
sampling the levels of drug in the blood, and by comparing these levels among the different
administration arms. Safety, tolerability, and immunologic response to the administered drugs
will also be evaluated throughout.